Nocardiosis future or investigational therapies

Nocardiosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Differentiating Nocardiosis from other Diseases
Epidemiology and Demographics
Causes
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Nocardiosis future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Nocardiosis future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Nocardiosis future or investigational therapies
CDC on Nocardiosis future or investigational therapies
Nocardiosis future or investigational therapies in the news
Blogs on Nocardiosis future or investigational therapies
Directions to Hospitals Treating Nocardiosis
Risk calculators and risk factors for Nocardiosis future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Future or Investigational Therapies

A new combination drug therapy (sulfonamide, ceftriaxone, and amikacin) has shown promise for treatment of infections not responding to standard antimicrobial treatments. Application of newer molecular diagnostic and subtyping methods may assist in earlier diagnosis.